George Whitesides Net Worth

The estimated Net Worth of George M Whitesides is at least $370 mil dollars as of 11 August 2017. George Whitesides owns over 4,000 units of Theravance Biopharma Inc stock worth over $32,400 and over the last 10 years he sold TBPH stock worth over $0. In addition, he makes $337,879 as Independent Director at Theravance Biopharma Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

George Whitesides TBPH stock SEC Form 4 insiders trading

George has made over 1 trades of the Theravance Biopharma Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 4,000 units of TBPH stock worth $98,760 on 11 August 2017.

The largest trade he's ever made was buying 4,000 units of Theravance Biopharma Inc stock on 11 August 2017 worth over $98,760. On average, George trades about 364 units every 0 days since 2014. As of 11 August 2017 he still owns at least 4,000 units of Theravance Biopharma Inc stock.

You can see the complete history of George Whitesides stock trades at the bottom of the page.

George Whitesides biography

Dr. George M. Whitesides Ph.D. serves as Independent Director of the Company., serves as an Independent Director of Company. Prior to our spin-off from Innoviva in June 2014 and since the inception of Innoviva in 1996, Dr. Whitesides served as a director of Innoviva. He has been Woodford L. and Ann A. Flowers University Professor at Harvard University since 2004. From 1986 to 2004, Dr. Whitesides was Mallinckrodt Professor of Chemistry at Harvard University. From 1982 to 1991 he was a member of the Department of Chemistry at Harvard University and Chairman of the Department of Chemistry from 1986 to 1989. He was a faculty member of the Massachusetts Institute of Technology from 1964 to 1982. Dr. Whitesides was a 1998 recipient of the National Medal of Science. He is a member of the editorial boards of 15 scientific journals. He is also a member of the board of directors of Nano Terra Inc., Arsenal Biomedical, Inc., Lyra Biomedical, Inc., Diagnostics for All, Inc. and Soft Robotics Inc. Dr. Whitesides holds a Ph.D. in Chemistry from the California Institute of Technology and a B.A. from Harvard University. . Whitesides' demonstrated leadership in his field, his knowledge of scientific matters affecting our business and his understanding of our industry contributed to our board's conclusion that he should serve as a director.

What is the salary of George Whitesides?

As the Independent Director of Theravance Biopharma Inc, the total compensation of George Whitesides at Theravance Biopharma Inc is $337,879. There are 18 executives at Theravance Biopharma Inc getting paid more, with Rick Winningham having the highest compensation of $5,932,410.

How old is George Whitesides?

George Whitesides is 80, he's been the Independent Director of Theravance Biopharma Inc since 2013. There are 1 older and 26 younger executives at Theravance Biopharma Inc. The oldest executive at Theravance Biopharma Inc is Burton Malkiel, 87, who is the Independent Director.

Insiders trading at Theravance Biopharma Inc

Over the last 11 years, insiders at Theravance Biopharma Inc have traded over $11,619,559 worth of Theravance Biopharma Inc stock and bought 4,008,513 units worth $29,986,832,769,275 . The most active insiders traders include Plc Gsk, Inc. Innoviva, y Eli Samaha. On average, Theravance Biopharma Inc executives and independent directors trade stock every 57 days with the average trade being worth of $448,635. The most recent stock trade was executed by Eli Samaha on 7 August 2024, trading 999,800 units of TBPH stock currently worth $7,798,440.

What does Theravance Biopharma Inc do?

theravance biopharma is a biopharmaceutical company with one approved product, vibativ® (telavancin), that was discovered and developed internally, a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies.

Complete history of George Whitesides stock trades at Theravance Biopharma Inc y Lyra Therapeutics

Theravance Biopharma Inc executives and stock owners

Theravance Biopharma Inc executives and other stock owners filed with the SEC include:

• Rick Winningham,
  Chairman of the Board, Chief Executive Officer
• Andrew Hindman,
  Chief Financial Officer, Senior Vice President
• Bradford Shafer,
  Executive Vice President, General Counsel, Secretary
• Brett Haumann,
  Senior Vice President, Clinical Development and Chief Medical Officer
• Frank Pasqualone,
  Senior Vice President and Chief Commercial Operations Officer
• Philip Worboys,
  Senior Vice President - Research and Translational Science
• Rick E. Winningham M.B.A.,
  Chairman & CEO
• Andrew Asa Hindman,
  Sr. VP & CFO
• Bradford J. Shafer,
  Exec. VP, Gen. Counsel & Sec.
• Andrew Asa Hindman M.B.A,
  Sr. VP & CFO
• Rhonda F. Farnum,
  Chief Bus. Officer and Sr. VP of Commercial & Medical Affairs
• William Young,
  Lead Independent Director
• Burton Malkiel,
  Independent Director
• Donal O'Connor,
  Independent Director
• Dean Mitchell,
  Independent Director
• Susan Molineaux,
  Independent Director
• Eran Broshy,
  Independent Director
• Laurie Alsup,
  Independent Director
• George Whitesides,
  Independent Director
• Robert Gunderson,
  Director
• Deepika Pakianathan,
  Independent Director
• Vijay Sabesan,
  Senior Vice President - Technical Operations
• Kenneth Pitzer,
  Senior Vice President - Product Strategy and Commercial Planning
• Ann Brady,
  President - Theravance Biopharma Ireland Limited
• Dr. Ann B. Brady Ph.D.,
  Pres of Theravance Biopharma Ireland Limited
• Dr. Richard A. Graham Ph.D.,
  Sr. VP of Devel.
• Daniel Long,
  Head of Medicinal Chemistry
• Dr. Kenneth R. Pitzer,
  Sr. VP of Product Strategy & Commercial Planning
• Dr. Phillip D. Worboys,
  Sr. VP of Research & Translational Science
• Dennis O. Driver,
  Sr. VP of HR, Organizational and Leadership Devel.
• Gail B. Cohen,
  VP of Corp. Communications & Investor Relations
• Jeremy T Grant,
  
• Renee D Gala,
  VP-Finance
• Peter S Ringrose,
  Director
• Junning Lee,
  Sr. VP, Technical Operations
• Sharathchandra S Hegde,
  SVP, Research
• Henrietta Fore,
  Director
• Shehnaaz Suliman,
  SVP, Corp Dev & Strategy
• Jeffrey David Jonker,
  Senior VP, Corp. & Bus. Dev.
• Michael G Atieh,
  Director
• Leonard M Blum,
  Sr VP, Chief Comm. Officer
• Inc. Innoviva,,
  10% owner
• Mathai Mammen,
  SVP, Research & Early Clin Dev
• Rhonda Farnum,
  SVP, COMM & MEDICAL AFFAIRS
• Richard A Graham,
  SVP, RESEARCH & DEVELOPMENT
• Plc Gsk,
  
• Aziz Sawaf,
  SVP & CHIEF FINANCIAL OFFICER
• Brett A. Grimaud,
  SVP, GEN COUNSEL AND SECRETARY
• Susannah Gray,
  
• Aine Miller,
  SVP, DEV & HEAD OF IRE OFFICE
• Eli Samaha,
  10% owner